| 前收盘价格 | 26.03 |
| 收盘价格 | 26.16 |
| 成交量 | 1,815,950 |
| 平均成交量 (3个月) | 1,721,159 |
| 市值 | 15,851,170,816 |
| 市盈率 (P/E TTM) | 16.77 |
| 预期市盈率 (P/E Forward) | 15.13 |
| 价格/销量 (P/S) | 4.23 |
| 股市价格/股市净资产 (P/B) | 2.64 |
| 52周波幅 | |
| 利润日期 | 7 May 2026 |
| 营业毛利率 | 35.27% |
| 营业利益率 (TTM) | 26.29% |
| 稀释每股收益 (EPS TTM) | 1.70 |
| 季度收入增长率 (YOY) | 18.60% |
| 季度盈利增长率 (YOY) | 1.60% |
| 总债务/股东权益 (D/E MRQ) | 2.70% |
| 流动比率 (MRQ) | 5.34 |
| 营业现金流 (OCF TTM) | 1.19 B |
| 杠杆自由现金流 (LFCF TTM) | 1.01 B |
| 资产报酬率 (ROA TTM) | 11.54% |
| 股东权益报酬率 (ROE TTM) | 22.80% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Genmab A/S | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.25 |
|
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Growth |
| 机构持股比例 | 10.31% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Brandywine Global Investment Management, Llc | 31 Dec 2025 | 1,031,464 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 41.50 (Jefferies, 60.73%) | 购买 |
| 中 | 40.00 (54.92%) | |
| 低 | 34.00 (Morgan Stanley, 31.68%) | 保留 |
| 平均值 | 39.10 (51.43%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 29.62 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wells Fargo | 02 Mar 2026 | 40.00 (54.92%) | 购买 | 29.65 |
| Guggenheim | 23 Feb 2026 | 40.00 (54.92%) | 购买 | 29.27 |
| HC Wainwright & Co. | 18 Feb 2026 | 40.00 (54.92%) | 购买 | 29.16 |
| 28 Jan 2026 | 39.00 (51.05%) | 购买 | 32.93 | |
| Jefferies | 17 Feb 2026 | 41.50 (60.73%) | 购买 | 30.00 |
| Morgan Stanley | 16 Feb 2026 | 34.00 (31.68%) | 保留 | 30.03 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合